131 related articles for article (PubMed ID: 23685175)
1. Synthesis and evaluation of novel orally active p53-MDM2 interaction inhibitors.
Miyazaki M; Naito H; Sugimoto Y; Yoshida K; Kawato H; Okayama T; Shimizu H; Miyazaki M; Kitagawa M; Seki T; Fukutake S; Shiose Y; Aonuma M; Soga T
Bioorg Med Chem; 2013 Jul; 21(14):4319-31. PubMed ID: 23685175
[TBL] [Abstract][Full Text] [Related]
2. Discovery of DS-5272 as a promising candidate: A potent and orally active p53-MDM2 interaction inhibitor.
Miyazaki M; Uoto K; Sugimoto Y; Naito H; Yoshida K; Okayama T; Kawato H; Miyazaki M; Kitagawa M; Seki T; Fukutake S; Aonuma M; Soga T
Bioorg Med Chem; 2015 May; 23(10):2360-7. PubMed ID: 25882531
[TBL] [Abstract][Full Text] [Related]
3. Lead optimization of novel p53-MDM2 interaction inhibitors possessing dihydroimidazothiazole scaffold.
Miyazaki M; Naito H; Sugimoto Y; Kawato H; Okayama T; Shimizu H; Miyazaki M; Kitagawa M; Seki T; Fukutake S; Aonuma M; Soga T
Bioorg Med Chem Lett; 2013 Feb; 23(3):728-32. PubMed ID: 23266121
[TBL] [Abstract][Full Text] [Related]
4. Discovery of novel dihydroimidazothiazole derivatives as p53-MDM2 protein-protein interaction inhibitors: synthesis, biological evaluation and structure-activity relationships.
Miyazaki M; Kawato H; Naito H; Ikeda M; Miyazaki M; Kitagawa M; Seki T; Fukutake S; Aonuma M; Soga T
Bioorg Med Chem Lett; 2012 Oct; 22(20):6338-42. PubMed ID: 22995624
[TBL] [Abstract][Full Text] [Related]
5. Discovery, synthesis, and biological evaluation of orally active pyrrolidone derivatives as novel inhibitors of p53-MDM2 protein-protein interaction.
Zhuang C; Miao Z; Zhu L; Dong G; Guo Z; Wang S; Zhang Y; Wu Y; Yao J; Sheng C; Zhang W
J Med Chem; 2012 Nov; 55(22):9630-42. PubMed ID: 23046248
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and biological evaluation of novel 3,4,5-trisubstituted aminothiophenes as inhibitors of p53-MDM2 interaction. Part 1.
Wang W; Shangguan S; Qiu N; Hu C; Zhang L; Hu Y
Bioorg Med Chem; 2013 Jun; 21(11):2879-85. PubMed ID: 23601819
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and biological evaluation of novel 3,4,5-trisubstituted aminothiophenes as inhibitors of p53-MDM2 interaction. Part 2.
Wang W; Lv D; Qiu N; Zhang L; Hu C; Hu Y
Bioorg Med Chem; 2013 Jun; 21(11):2886-94. PubMed ID: 23611770
[TBL] [Abstract][Full Text] [Related]
8. Rational design and binding mode duality of MDM2-p53 inhibitors.
Gonzalez-Lopez de Turiso F; Sun D; Rew Y; Bartberger MD; Beck HP; Canon J; Chen A; Chow D; Correll TL; Huang X; Julian LD; Kayser F; Lo MC; Long AM; McMinn D; Oliner JD; Osgood T; Powers JP; Saiki AY; Schneider S; Shaffer P; Xiao SH; Yakowec P; Yan X; Ye Q; Yu D; Zhao X; Zhou J; Medina JC; Olson SH
J Med Chem; 2013 May; 56(10):4053-70. PubMed ID: 23597064
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and biological evaluation of imidazoline derivatives as p53-MDM2 binding inhibitors.
Hu C; Li X; Wang W; Zhang L; Tao L; Dong X; Sheng R; Yang B; Hu Y
Bioorg Med Chem; 2011 Sep; 19(18):5454-61. PubMed ID: 21855354
[TBL] [Abstract][Full Text] [Related]
10. Tetra-substituted imidazoles as a new class of inhibitors of the p53-MDM2 interaction.
Vaupel A; Bold G; De Pover A; Stachyra-Valat T; Lisztwan JH; Kallen J; Masuya K; Furet P
Bioorg Med Chem Lett; 2014 May; 24(9):2110-4. PubMed ID: 24704029
[TBL] [Abstract][Full Text] [Related]
11. Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical development.
Sun D; Li Z; Rew Y; Gribble M; Bartberger MD; Beck HP; Canon J; Chen A; Chen X; Chow D; Deignan J; Duquette J; Eksterowicz J; Fisher B; Fox BM; Fu J; Gonzalez AZ; Gonzalez-Lopez De Turiso F; Houze JB; Huang X; Jiang M; Jin L; Kayser F; Liu JJ; Lo MC; Long AM; Lucas B; McGee LR; McIntosh J; Mihalic J; Oliner JD; Osgood T; Peterson ML; Roveto P; Saiki AY; Shaffer P; Toteva M; Wang Y; Wang YC; Wortman S; Yakowec P; Yan X; Ye Q; Yu D; Yu M; Zhao X; Zhou J; Zhu J; Olson SH; Medina JC
J Med Chem; 2014 Feb; 57(4):1454-72. PubMed ID: 24456472
[TBL] [Abstract][Full Text] [Related]
12. Selective and potent morpholinone inhibitors of the MDM2-p53 protein-protein interaction.
Gonzalez AZ; Eksterowicz J; Bartberger MD; Beck HP; Canon J; Chen A; Chow D; Duquette J; Fox BM; Fu J; Huang X; Houze JB; Jin L; Li Y; Li Z; Ling Y; Lo MC; Long AM; McGee LR; McIntosh J; McMinn DL; Oliner JD; Osgood T; Rew Y; Saiki AY; Shaffer P; Wortman S; Yakowec P; Yan X; Ye Q; Yu D; Zhao X; Zhou J; Olson SH; Medina JC; Sun D
J Med Chem; 2014 Mar; 57(6):2472-88. PubMed ID: 24548297
[TBL] [Abstract][Full Text] [Related]
13. Discovery of 1-arylpyrrolidone derivatives as potent p53-MDM2 inhibitors based on molecule fusing strategy.
Li J; Wu Y; Guo Z; Zhuang C; Yao J; Dong G; Yu Z; Min X; Wang S; Liu Y; Wu S; Zhu S; Sheng C; Miao Z; Zhang W
Bioorg Med Chem Lett; 2014 Jun; 24(12):2648-50. PubMed ID: 24813735
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and CoMFA studies of N1-amino acid substituted 2,4,5-triphenyl imidazoline derivatives as p53-MDM2 binding inhibitors.
Hu C; Dou X; Wu Y; Zhang L; Hu Y
Bioorg Med Chem; 2012 Feb; 20(4):1417-24. PubMed ID: 22273545
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and biological evaluation of novel antitumor spirotetrahydrothiopyran-oxindole derivatives as potent p53-MDM2 inhibitors.
Ji C; Wang S; Chen S; He S; Jiang Y; Miao Z; Li J; Sheng C
Bioorg Med Chem; 2017 Oct; 25(20):5268-5277. PubMed ID: 28797774
[TBL] [Abstract][Full Text] [Related]
16. Optimization beyond AMG 232: discovery and SAR of sulfonamides on a piperidinone scaffold as potent inhibitors of the MDM2-p53 protein-protein interaction.
Wang Y; Zhu J; Liu JJ; Chen X; Mihalic J; Deignan J; Yu M; Sun D; Kayser F; McGee LR; Lo MC; Chen A; Zhou J; Ye Q; Huang X; Long AM; Yakowec P; Oliner JD; Olson SH; Medina JC
Bioorg Med Chem Lett; 2014 Aug; 24(16):3782-5. PubMed ID: 25042256
[TBL] [Abstract][Full Text] [Related]
17. Novel inhibitors of the MDM2-p53 interaction featuring hydrogen bond acceptors as carboxylic acid isosteres.
Gonzalez AZ; Li Z; Beck HP; Canon J; Chen A; Chow D; Duquette J; Eksterowicz J; Fox BM; Fu J; Huang X; Houze J; Jin L; Li Y; Ling Y; Lo MC; Long AM; McGee LR; McIntosh J; Oliner JD; Osgood T; Rew Y; Saiki AY; Shaffer P; Wortman S; Yakowec P; Yan X; Ye Q; Yu D; Zhao X; Zhou J; Olson SH; Sun D; Medina JC
J Med Chem; 2014 Apr; 57(7):2963-88. PubMed ID: 24601644
[TBL] [Abstract][Full Text] [Related]
18. One-pot synthesis of spiro(indoline-3,4'-pyrazolo[3,4-b]pyridine)-5'-carbonitriles as p53-MDM2 interaction inhibitors.
Ibrahim HS; Eldehna WM; Fallacara AL; Ahmed ER; Ghabbour HA; Elaasser MM; Botta M; Abou-Seri SM; Abdel-Aziz HA
Future Med Chem; 2018 Dec; 10(24):2771-2789. PubMed ID: 30526032
[TBL] [Abstract][Full Text] [Related]
19. Structure-based design of novel inhibitors of the MDM2-p53 interaction.
Rew Y; Sun D; Gonzalez-Lopez De Turiso F; Bartberger MD; Beck HP; Canon J; Chen A; Chow D; Deignan J; Fox BM; Gustin D; Huang X; Jiang M; Jiao X; Jin L; Kayser F; Kopecky DJ; Li Y; Lo MC; Long AM; Michelsen K; Oliner JD; Osgood T; Ragains M; Saiki AY; Schneider S; Toteva M; Yakowec P; Yan X; Ye Q; Yu D; Zhao X; Zhou J; Medina JC; Olson SH
J Med Chem; 2012 Jun; 55(11):4936-54. PubMed ID: 22524527
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluation of novel potent MDM2/p53 small-molecule inhibitors.
Ivanenkov YA; Vasilevski SV; Beloglazkina EK; Kukushkin ME; Machulkin AE; Veselov MS; Chufarova NV; Chernyaginab ES; Vanzcool AS; Zyk NV; Skvortsov DA; Khutornenko AA; Rusanov AL; Tonevitsky AG; Dontsova OA; Majouga AG
Bioorg Med Chem Lett; 2015 Jan; 25(2):404-9. PubMed ID: 25479770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
